Chondroitin sulfate mediates liver responses to injury induced by dual endothelin receptor inhibition.
Sign Up to like & getrecommendations! Published in 2020 at "Canadian journal of physiology and pharmacology"
DOI: 10.1139/cjpp-2019-0649
Abstract: Although dual endothelin receptor antagonists (ERAs) show great promise for treating various conditions, their propensity to induce liver injury limits their clinical usage. Inflammation and fibrosis are important processes in liver responses to injury and… read more here.
Keywords: inhibition; dual endothelin; endothelin receptor; chst3 chst13 ... See more keywords
Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Respiratory Disease"
DOI: 10.1177/1753466618823440
Abstract: Macitentan (10 mg once daily orally), a dual endothelin receptor antagonist (ERA) developed by modifying the structure of bosentan to increase the efficacity and safety, is approved for the treatment of pulmonary arterial hypertension (PAH). The… read more here.
Keywords: receptor antagonist; trial; treatment; dual endothelin ... See more keywords
Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension
Sign Up to like & getrecommendations! Published in 2023 at "Life"
DOI: 10.3390/life13030806
Abstract: Resistant hypertension (RH) is defined as the failure to achieve blood pressure control despite using triple combination therapy with a renin-angiotensin system inhibitor (RAS-i), a calcium antagonist, and a diuretic. The endothelin (ET) system is… read more here.
Keywords: dual endothelin; hypertension; novel dual; management ... See more keywords